CPS-11
Based on 1 Customer Validation
CPS-11 (N-(Hydroxymethyl)thalidomide) a Thalidomide (HY-14658) analogue, is a potent anti-cancer agent. CPS-11 inhibits NF-κB, activates NFAT, and repress cytokine expression through elevated ROS. CPS-11 exhibits a wider activity spectrum and higher potency against MM (multiple myeloma) cell lines.
For research use only. We do not sell to patients.
- Purity : 99.39%
- CAS No.: 145945-21-7
- Formula: C14H12N2O5
- Molecular Weight:288.26
-
Storage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
In Vitro
CPS-11 abrogates ability of bone marrow stromal cells (BMSCs) to induce proliferation of MM cells, confirming its ability to target tumor cells in the bone marrow microenvironment[1].
CPS-11 (0-200 μM, 0 or 4 h) shows virtually no effect on activation of p38 and only slight, transient activation of ATF2 and HSP27[2].
CPS-11 (0-100 μM, 24 or 48 h) was no toxic to H157 cells, WT MEFs or the p38α-/- MEFs at doses as high as 100 μM[2].
CPS-11 (50 μM, 24 or 48 h) does not induce apoptosis in H157 cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:H157 cells, PC3 cells, HUVEC cells
-
Concentration:0, 1, 5, 10, 20, 50, 100 and 200 μM
-
Incubation Time:0, 15 min, 30 min, 1 h, 2 h, and 4 h
-
Result:Showed virtually no effect on activation of p38 and only slight, transient activation of ATF2 and HSP27. Increased Akt phosphorylation within 15 minutes, and decreased Akt phosphorylation from 15 minutes to 4 hours.
-
Cell Line:H157 cells, wild-type (WT) mouse embryonic fibroblasts (MEF) and p38α-/- MEF
-
Concentration:0, 20, 50, and 100 μM
-
Incubation Time:24 or 48 hours
-
Result:Showed no toxic to H157 cells at doses as high as 100 μM and an incubation time of 48 hours. had no toxic effect on either the WT MEFs or the p38α-/- MEFs at doses as high as 100 μM.
-
Cell Line:H157 cells
-
Concentration:50 μM
-
Incubation Time:24 or 48 hours
-
Result:Did not induce apoptosis in H157 cells at either time point.
Chemical Information
-
CAS No. 145945-21-7
-
Appearance Solid
-
Molecular Weight 288.26
-
Formula C14H12N2O5
-
Color White to off-white
-
SMILES
O=C1N(C(C2=C1C=CC=C2)=O)C(C(N3CO)=O)CCC3=O
-
Synonyms
N-(Hydroxymethyl)thalidomide
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Solvent & Solubility
In Vitro:
DMSO : 57.7 mg/mL (200.17 mM; Need ultrasonic and warming; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Purity & Documentation
-
Data Sheet (277 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Aragon-Ching JB, et al. Thalidomide analogues as anticancer drugs. Recent Pat Anticancer Drug Discov. 2007 Jun;2(2):167-74. [Content Brief]
[2]. Warfel NA, et al. Importance of the stress kinase p38alpha in mediating the direct cytotoxic effects of the thalidomide analogue, CPS49, in cancer cells and endothelial cells. Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3502-9. [Content Brief]
[3]. Ge Y, et al. Selective leukemic-cell killing by a novel functional class of thalidomide analogs. Blood. 2006 Dec 15;108(13):4126-35. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.4691 mL | 17.3455 mL | 34.6909 mL | 86.7273 mL |
| 5 mM | 0.6938 mL | 3.4691 mL | 6.9382 mL | 17.3455 mL | |
| 10 mM | 0.3469 mL | 1.7345 mL | 3.4691 mL | 8.6727 mL | |
| 15 mM | 0.2313 mL | 1.1564 mL | 2.3127 mL | 5.7818 mL | |
| 20 mM | 0.1735 mL | 0.8673 mL | 1.7345 mL | 4.3364 mL | |
| 25 mM | 0.1388 mL | 0.6938 mL | 1.3876 mL | 3.4691 mL | |
| 30 mM | 0.1156 mL | 0.5782 mL | 1.1564 mL | 2.8909 mL | |
| 40 mM | 0.0867 mL | 0.4336 mL | 0.8673 mL | 2.1682 mL | |
| 50 mM | 0.0694 mL | 0.3469 mL | 0.6938 mL | 1.7345 mL | |
| 60 mM | 0.0578 mL | 0.2891 mL | 0.5782 mL | 1.4455 mL | |
| 80 mM | 0.0434 mL | 0.2168 mL | 0.4336 mL | 1.0841 mL | |
| 100 mM | 0.0347 mL | 0.1735 mL | 0.3469 mL | 0.8673 mL |
CPS-11 Related Classifications
HY-117987 Related Classifications
Powered by Bioz
Keywords
- CPS-11
- 145945-21-7
- N-(Hydroxymethyl)thalidomide
- CPS11
- CPS 11
- Nuclear Factor of activated T Cells (NFAT)
- NF-κB
- Reactive Oxygen Species (ROS)
- H157 cells
- PC3 cells
- H1703 cells
- mouse embryonic fibroblasts
- MEF
- p38
- bone marrow stromal cells
- BMSC
- ATF2
- HSP27
- Multiple Myeloma
- MM
- Prostate cancer
- Thalidomide
- Inhibitor
- inhibitor
- inhibit